Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies
Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies
复制标题
DOI：
10.1016/j.jdermsci.2021.10.003
复制
发表时间：
2021-12-13
影响因子：
4.6
通讯作者：
Fujimoto, Manabu
中科院分区：
文献类型：
--
作者：
Nhung Thi My Ly;Ma, Ni;Fujimoto, Manabu
背景：皮肌炎（DM）是一种慢性获得性自身免疫性疾病，与癌症的发生密切相关。到目前为止，识别表明癌症高风险的预测标志物一直是临床医生的挑战。虽然抗TIF 1 γ抗体是一个主要的血清学指标，癌症相关的DM，许多抗TIF 1 γ抗体阳性DM患者缺乏malignancy.Objectives：为了确定临床和实验室参数，支持癌症预测在抗TIF 1 γ抗体阳性DM patients.Methods：临床和实验室数据收集癌症相关和非相关的DM患者与抗TIF 1 γ抗体。用细胞因子阵列测定法测定血清细胞因子浓度。用受试者工作特征曲线分析确定了炎症细胞因子在癌症预后中的价值。结果：癌症组中男性的频率显著较高，平均年龄较大，抗TIF 1 γ抗体水平较高。一些炎性细胞因子，特别是肿瘤坏死因子（TNF）和TNF受体超家族，血清中的水平增加，与肌炎标志物，皮肤的严重程度和DM疾病的活动。此外，这些细胞因子的曲线下面积（AUC）>= 0.8，并且在其特定截止值处具有高灵敏度和特异性，甚至高于我们的DM患者中癌症预测中的抗TIF 1 γ水平。我们的研究结果表明，肌炎，抗TIF 1 γ抗体阳性的糖尿病患者的癌症和皮肤受累以及抗TIF 1 γ抗体的潜在临床意义TIF 1 γ抗体水平在评估糖尿病患者疾病严重程度和预后中的作用一些炎性细胞因子，特别是TNF和TNF受体超家族，包括BAFF，sTNF-R1和sTNF-R2，可能支持抗TIF 1 γ抗体的DM患者的癌症预测。(C)2021由Elsevier B. V.代表日本皮肤病研究学会出版。
Background: Dermatomyositis (DM) is a chronic acquired autoimmune disorder strongly associated with cancer development. Until now, identifying predictive markers indicating a high risk of cancer has challenged clinicians. Although anti-TIF1 gamma antibody is a major serological indicator for cancer-associated DM, many anti-TIF1 gamma antibody-positive DM patients lack malignancy.Objectives: To determine clinical and laboratory parameters that support cancer prediction in anti-TIF1 gamma antibody-positive DM patients.Methods: Clinical and laboratory data were collected from cancer-associated and unassociated DM patients with anti-TIF1 gamma antibodies. Serum cytokine concentrations were measured with a cytokine array assay. The values of inflammatory cytokines in cancer prognosis were determined with a receiver operating characteristic curve analysis.Results: The cancer group had a significantly higher frequency of males, older mean age and higher anti-TIF1 gamma antibody levels. Some inflammatory cytokines, particularly tumour necrosis factor (TNF) and TNF receptor superfamilies, had increased levels in sera that were correlated with myositis markers, cutaneous severity and DM disease activity. Moreover, these cytokines had an area under the curve (AUC) >= 0.8 and high sensitivity and specificity at their specific cut-off, even higher than anti-TIF1 gamma levels in cancer prediction in our DM patients.Conclusions: Our results suggest a close pathophysiological relationship among myositis, cancer and skin involvements in DM patients with anti-TIF1 gamma antibodies and the potential clinical significance of anti-TIF1 gamma antibody levels in evaluating disease severity and prognosis in DM patients. Some inflammatory cytokines, particularly TNF and TNF receptor superfamilies including BAFF, sTNF-R1 and sTNF-R2, may support cancer prediction in DM patients with anti-TIF1 gamma antibodies. (C) 2021 Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.